GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (NAS:UTHR) » Definitions » Cyclically Adjusted Book per Share

United Therapeutics (United Therapeutics) Cyclically Adjusted Book per Share : $72.25 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is United Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

United Therapeutics's adjusted book value per share for the three months ended in Dec. 2023 was $127.227. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $72.25 for the trailing ten years ended in Dec. 2023.

During the past 12 months, United Therapeutics's average Cyclically Adjusted Book Growth Rate was 17.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 20.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 19.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 19.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of United Therapeutics was 22.10% per year. The lowest was 17.10% per year. And the median was 18.70% per year.

As of today (2024-04-28), United Therapeutics's current stock price is $233.85. United Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $72.25. United Therapeutics's Cyclically Adjusted PB Ratio of today is 3.24.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of United Therapeutics was 12.58. The lowest was 2.27. And the median was 4.40.


United Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for United Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Cyclically Adjusted Book per Share Chart

United Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.69 41.68 50.92 61.46 72.25

United Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.46 64.51 67.33 70.13 72.25

Competitive Comparison of United Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, United Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, United Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Cyclically Adjusted PB Ratio falls into.



United Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, United Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=127.227/129.4194*129.4194
=127.227

Current CPI (Dec. 2023) = 129.4194.

United Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 26.492 99.695 34.391
201406 24.855 100.560 31.988
201409 24.884 100.428 32.068
201412 26.373 99.070 34.452
201503 23.542 99.621 30.584
201506 22.771 100.684 29.270
201509 32.180 100.392 41.485
201512 34.715 99.792 45.021
201603 38.138 100.470 49.127
201606 41.301 101.688 52.564
201609 43.099 101.861 54.759
201612 43.088 101.863 54.745
201703 45.842 102.862 57.678
201706 40.890 103.349 51.205
201709 47.907 104.136 59.539
201712 48.608 104.011 60.482
201803 54.549 105.290 67.050
201806 58.895 106.317 71.693
201809 61.781 106.507 75.072
201812 63.976 105.998 78.112
201903 52.938 107.251 63.880
201906 58.346 108.070 69.873
201909 61.891 108.329 73.940
201912 63.357 108.420 75.628
202003 67.008 108.902 79.633
202006 69.746 108.767 82.989
202009 73.877 109.815 87.066
202012 76.284 109.897 89.835
202103 76.926 111.754 89.086
202106 81.075 114.631 91.534
202109 85.064 115.734 95.122
202112 87.765 117.630 96.562
202203 92.217 121.301 98.389
202206 94.931 125.017 98.274
202209 100.129 125.227 103.482
202212 104.203 125.222 107.696
202303 109.708 127.348 111.493
202306 115.340 128.729 115.959
202309 121.583 129.860 121.171
202312 127.227 129.419 127.227

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


United Therapeutics  (NAS:UTHR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

United Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=233.85/72.25
=3.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of United Therapeutics was 12.58. The lowest was 2.27. And the median was 4.40.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


United Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics (United Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Executives
Paul A Mahon officer: EVP & General Counsel
Nilda Mesa director C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Causey director
Martine A Rothblatt director, officer: Chief Executive Officer
Louis W Sullivan director
Judy D. Olian director 2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067
Michael Benkowitz officer: President and COO C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Patusky director
Raymond Dwek director
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Katherine J Klein director STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104
Richard Giltner director C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009
Roger Jeffs director, officer: President and COO
David Zaccardelli officer: EVP & Chief Operating Officer 300 TRI STATE INTERNATIONAL, SUITE 272, LINCOLNSHIRE IL 60069